Real-World Analysis Shows Similar Safety, Efficacy With Teclistamab in RRMM
December 9th 2023The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.
Read More
Neoadjuvant Nivolumab/Carboplatin/Paclitaxel Delivers High pCR Rates in Early-Stage TNBC
December 9th 2023Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.
Read More
Survival Benefit With Neoadjuvant Pembro/Chemo, Adjuvant Pembro Upheld in High-Risk Early TNBC
December 9th 2023Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.
Read More
No Significant pCR Improvement With Neoadjuvant HP/Chemo Plus Atezolizumab in HER2+ Breast Cancer
December 8th 2023The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.
Read More
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2-Positive Early Breast Cancer
December 8th 2023After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.
Read More
SIM0270 Shows Early Antitumor Activity in ER+/HER2– Advanced/Metastatic Breast Cancer
December 8th 2023The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.
Read More
Adding Ribociclib to Aromatase Inhibitor Treatment Improves iDFS in Early Breast Cancer
December 8th 2023Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone.
Read More
Graff on Using the Signatera Assay to Assess ctDNA in Early Breast Cancer
December 8th 2023Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Watch
T-DXd Shows Early Survival Advantage in Advanced Breast Cancer and Leptomeningeal Carcinomatosis
December 7th 2023Early findings from the DEBBRAH study suggest that fam-trastuzumab deruxtecan-nxki shows potential in treating patients with advanced HER2-positive, HER2-low breast cancer, including those with leptomeningeal carcinomatosis.
Read More
Longer PFS with Dato-Dxd in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Read More
Trastuzumab Deruxtecan Shows Activity in Real-World mBC With Dynamic HER2
December 7th 2023The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.
Read More
Survival Disparities Shown With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer
December 7th 2023Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.
Read More
Tucatinib Plus T-DM1 Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Read More
Neoadjuvant Chemo/Pembro Betters pCR in Key ER+ Breast Cancer Subgroups
December 6th 2023Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.
Read More
ctDNA May Identify Risk of Recurrence in Early Breast Cancer Subgroup
December 6th 2023Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.
Read More
Capivasertib Shows Superior PROs Vs Placebo in HR+, HER2- Breast Cancer
December 6th 2023Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Read More